Leon O Moulder Jr. - 07 Jan 2026 Form 4 Insider Report for Zenas BioPharma, Inc. (ZBIO)

Signature
By: /s/ Chase Jayasekera, Attorney-in-Fact
Issuer symbol
ZBIO
Transactions as of
07 Jan 2026
Net transactions value
+$1,639,000
Form type
4
Filing time
09 Jan 2026, 21:42:58 UTC
Previous filing
09 Oct 2025
Next filing
03 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
MOULDER LEON O JR Chief Executive Officer, Director C/O ZENAS BIOPHARMA, INC., 852 WINTER STREET, SUITE 250, WALTHAM By: /s/ Chase Jayasekera, Attorney-in-Fact 09 Jan 2026 0001228865

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZBIO Common Stock Purchase $819,000 +50,000 +19% $16.38 316,155 07 Jan 2026 Direct F1
transaction ZBIO Common Stock Purchase $489,000 +30,000 +9.5% $16.30 346,155 08 Jan 2026 Direct F2
transaction ZBIO Common Stock Purchase $331,000 +20,000 +5.8% $16.55 366,155 09 Jan 2026 Direct F3
holding ZBIO Common Stock 36,928 07 Jan 2026 See Footnote F4
holding ZBIO Common Stock 1,672,039 07 Jan 2026 See Footnote F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $16.21 to $16.53, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2 The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $15.82 to $16.60, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F3 The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $16.05 to $16.87, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F4 The reporting person is a Trustee of the the Leon O. Moulder, Jr. Revocable Trust U/A dtd 9/9/2008 (the "Trust") and may be deemed to have voting and dispositive power over the shares held by the Trust. The reporting person is the Issuer's chief executive officer and Chairman of its board of directors. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F5 Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.